The FDA approved Tauklarify, a new brain-imaging drug, on August 14, 2026, to help diagnose Alzheimer's disease by detecting a protein called tau. It won't settle a younger-onset diagnosis on its own, so a family should know what the scan can and can't show before scheduling one.
Tauklarify (florquinitau F 18 injection, also called MK-6240) is a radioactive tracer injected before a PET scan to estimate the density of tau neurofibrillary tangles — twisted protein fibers inside brain cells that build up in Alzheimer's disease. Lantheus's FDA approval announcement describes it as approved for adults with cognitive impairment who are being evaluated for Alzheimer's. For a family watching a relative develop symptoms in their 40s, 50s, or early 60s, the scan adds a new, more direct piece of evidence than earlier Alzheimer's tests offered — but it still needs to be interpreted inside a larger diagnostic picture.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from NIH — Use this primary source to verify the official guidance.
- Read the official notice from Barchart — Use this primary source to verify the official announcement.
Table of Contents
- What does this approval actually add to the diagnostic workup?
- Is this scan validated for younger-onset or atypical symptoms?
- How accurate is a Tauklarify result, and what could go wrong?
- What does the appointment involve, and are there safety restrictions?
- Will insurance or Medicare cover the scan?
- Frequently Asked Questions
What does this approval actually add to the diagnostic workup?
Tauklarify is only the second F-18-labeled tau PET tracer approved in the United States, following Eli Lilly's Tauvid in 2020, according to NeurologyLive. That gives clinicians a second validated option for imaging tau pathology directly in a living patient's brain, rather than relying only on amyloid scans, cognitive testing, or cerebrospinal fluid markers.
Families can ask a clinician directly whether Tauklarify or Tauvid is the better fit for their relative's case, since both are now FDA-approved and a 2026 head-to-head comparison exists. The Lancet-published HEAD study enrolled 775 participants across eight North American sites, with 682 completing both tracers' scans within 45 days, giving clinicians comparative data between the two agents, as reported by NeurologyLive. A reasonable question to bring to an appointment: "Is this scan being ordered because amyloid testing was inconclusive, or to confirm a diagnosis cognitive testing already suggests?" The answer shapes how much weight the result should carry.
Is this scan validated for younger-onset or atypical symptoms?
This is the question most relevant to younger-onset families, and it has a specific answer worth bringing up directly. The FDA states that Tauklarify's safety and effectiveness have not been established for evaluating non-Alzheimer's tauopathies — other conditions that also involve tau buildup but are not Alzheimer's disease, according to Healio.
Younger-onset dementia has a wider range of possible underlying causes than late-onset dementia, including some atypical tauopathies. A family should ask a clinician whether the relative's symptom pattern — language difficulty, visual-spatial problems, or behavioral changes rather than memory loss alone — fits typical Alzheimer's or looks more like one of the atypical conditions this scan was not built to evaluate.
- Ask: "Does my relative's symptom pattern match classic Alzheimer's, or does it look atypical?"
- Ask: "If the scan comes back negative, does that rule out Alzheimer's, or could it still be an atypical tauopathy this tracer isn't validated for?"
How accurate is a Tauklarify result, and what could go wrong?
Approval rested on two blinded-reader studies covering more than 500 subjects. Readers agreed with the reference standard on positive results 68% to 88% of the time, and on negative results 93% to 99% of the time, per Healio. That range means a positive scan carries a meaningfully higher chance of disagreement among readers than a negative one, and false results in either direction are possible. A positive or negative result does not, by itself, confirm or rule out Alzheimer's-related tau pathology.
NeurologyLive reports that clinicians must weigh the scan alongside cognitive testing and other biomarkers before reaching a diagnosis. A family can ask a clinician to walk through exactly what other tests — memory and language assessments, blood or spinal fluid markers, an amyloid scan — will be combined with the Tauklarify result, and what each outcome combination would mean for next steps. One data point specific to younger-onset disease is worth raising directly: in the LEADS study, 231 of 243 amyloid-positive younger patients — about 95% — were also tau-PET positive, and typically showed a higher tau burden than is usually seen in late-onset Alzheimer's, according to research cited in PMC. That suggests a younger-onset relative with confirmed amyloid pathology is likely to show a clear tau signal, rather than an ambiguous one.
What does the appointment involve, and are there safety restrictions?
The procedure is a single intravenous injection of the tracer, given about 90 minutes before imaging; the PET scan itself takes roughly 20 minutes, according to Drugs.com. That timeline is useful for planning a visit, especially for a patient who may become anxious or fatigued during a longer appointment.
Safety data from 1,734 people showed headache was the most common side effect at 0.7%, with nausea (0.2%) and injection-site reactions (0.1%) also reported, per Psychiatric Times. The same source notes that Tauklarify should not be used with CYP1A2 inducers — a category that includes tobacco — within seven days of the scan, since those substances can interfere with the tracer's behavior in the body.
- Ask: "Does my relative take any medications or use tobacco that could interact with the tracer in the week before the scan?"
- Ask: "What side effects should we watch for after the injection, and for how long?"
Will insurance or Medicare cover the scan?
Cost and coverage are practical questions worth raising before scheduling. As of August 2026 reporting, no source confirms a Medicare or CMS national coverage decision or a specific price for Tauklarify, and CMS has historically covered amyloid PET only narrowly, often limited to clinical-study settings, according to Radiology Business.
A family should ask the ordering clinician or the imaging center directly what the scan will cost out of pocket, whether the relative's specific insurance plan covers tau PET imaging, and whether a clinical trial or research study might offer the scan at reduced or no cost. Getting a written cost estimate before the appointment avoids a surprise bill for a test whose coverage rules are still unsettled.
Frequently Asked Questions
Can Tauklarify diagnose early-onset Alzheimer's by itself?
No. A positive or negative result must be combined with cognitive testing and other biomarkers, according to NeurologyLive.
How is Tauklarify different from Tauvid, the other approved tau tracer?
Both are F-18-labeled tau PET agents; a 2026 head-to-head trial in The Lancet compared them directly across 775 participants, giving clinicians comparative data to choose between them, per NeurologyLive.
Is the scan validated for atypical or non-Alzheimer's dementias sometimes seen in younger patients?
No. The FDA states its safety and effectiveness have not been established for non-Alzheimer's tauopathies, per Healio.
What should someone avoid before the scan?
CYP1A2 inducers, including tobacco, within seven days of the injection, according to Psychiatric Times.
You Might Also Like
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Questions Younger-Onset Alzheimer’s Families Can Bring to a Clinician
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Questions Younger-Onset Alzheimer’s Families Can Bring to a Clinician
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Questions Younger-Onset Alzheimer’s Families Can Bring to a Clinician
